1. Демографический ежегодник России. 2013. URL: http://www.gks.ru/bgd/regl/ B13_16/Main. htm
[Demograficheskii ezhegodnik Rossii. 2013. http://www.gks.ru/bgd/regl/ B13_16/Main. htm (in Russian).]
2. Трухан Д.И., Викторова И.А. Внутренние болезни: Кардиология. Ревматология. М.: ООО «Медицинское информационное агентство», 2013.
[Trukhan D.I., Viktorova I.A. Internal Medicine: Cardiology. Rheumatology. Moscow: OOO "Meditsinskoe informatsionnoe agentstvo", 2013 (in Russian).]
3. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Общество специалистов по сердечной недостаточности. Российское кардиологическое общество. 2016. URL: http://ossn.ru/upload/medialibrary/003/97_30012017.pdf
[Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). Obshchestvo spetsialistov po serdechnoi nedostatochnosti. Rossiiskoe kardiologicheskoe obshchestvo. 2016. URL: http://ossn.ru/upload/medialibrary/003/97_30012017.pdf (in Russian).]
4. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Рос. кардиол. журн. 2016; 8: 7–13.
[Fomin I.V. Khronicheskaia serdechnaia nedostatochnost' v Rossiiskoi Federatsii: chto segodnia my znaem i chto dolzhny delat'. Ros. kardiol. zhurn. 2016; 8: 7–13 (in Russian).]
5. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) Журн. Сердечная Недостаточность. 2013; 7 (81): 379–472.
[Mareev V.Iu., Ageev F.T., Arutiunov G.P. et al. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr) Zhurn. Serdechnaia Nedostatochnost'. 2013; 7 (81): 379–472 (in Russian).]
6. Трухан Д.И., Филимонов С.Н. Болезни сердечно-сосудистой системы: клиника, диагностика и лечение. СПб.: СпецЛит, 2016.
[Trukhan D.I., Filimonov S.N. Bolezni serdechno-sosudistoi sistemy: klinika, diagnostika i lechenie. Saint Petersburg: SpetsLit, 2016 (in Russian).]
7. Темникова Е.А., Филимонов С.Н., Трухан Д.И. Гериатрические аспекты заболеваний сердечно-сосудистой системы. Новокузнецк: Полиграфист, 2019.
[Temnikova E.A., Filimonov S.N., Trukhan D.I. Geriatricheskie aspekty zabolevanii serdechno-sosudistoi sistemy. Novokuznetsk: Poligrafist, 2019 (in Russian).]
8. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиолог. журн. 2006; 4: 45–50.
[Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. et al. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiolog. zhurn. 2006; 4: 45–50 (in Russian).]
9. Шальнова С., Кукушкин С., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии. Врач. 2009; 12: 39–42.
[Shal'nova S., Kukushkin S., Manoshkina E., Timofeeva T. Arterial'naia gipertenziia i priverzhennost' terapii. Vrach. 2009; 12: 39–42 (in Russian).]
10. Трухан Д.И. Лечение хронической сердечной недостаточности и артериальной гипертензии: две цели и один препарат – торасемид. Consilium Medicum. 2017; 19 (10): 79–84. DOI: 10.26442/2075-1753_19.10.79-84
[Trukhan D.I. Treatment of chronic heart failure and arterial hypertension: two aims and one drug – torasemide. Consilium Medicum. 2017; 19 (10): 79–84. DOI: 10.26442/2075-1753_19.10.79-84 (in Russian).]
11. Трухан Д.И. Артериальная гипертензия и хроническая сердечная недостаточность: две цели и один препарат – фозиноприл. Consilium Medicum. 2018; 20 (5): 50–5. DOI: 10.26442/2075-1753_2018.5.50-55
[Trukhan D.I. Treatment of chronic heart failure and arterial hypertension: two aims and one drug – fosinopril. Consilium Medicum. 2018; 20 (5): 50–55. DOI: 10.26442/2075-1753_2018.5.50-55 (in Russian).]
12. Masereel B, Ferrari P, Ferrandi M et al. Na+, 2Cl-, K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
13. Диувер (Diuver) инструкция по применению. URL: https://www.vidal.ru/drugs/diuver__8865
[Diuver (Diuver) instruktsiia po primeneniiu. URL: https://www.vidal.ru/drugs/diuver__8865 (in Russian).]
14. Reyes AJ. Effects of diuretics on renal excretory function. Eur Heart J 1992; 13 (Suppl. G): 15–21.
15. Bolke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs of Today 1994; 30 (8): 1–28.
16. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–42.
17. Fortuno A, Muniz P, Ravassa S et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 1999; 34 (1): 138–43.
18. Spieker C, Zidek W, Hacker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1A): 188–90.
19. López B, Querejeta R, González A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43 (11): 2028–35.
20. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
21. Kasama S, Toyama T, Sumino H et al. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. Int J Cardiol 2013; 167 (1): 244–9.
22. Harada K, Izawa H, Nishizawa T et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol 2009; 53 (6): 468–73.
23. Guan Z, Pollock JS, Cook AK et al. Effect of epithelial sodium channel blockade on the myogenic response of rat juxtamedullary afferent arterioles. Hypertension 2009; 54 (5): 1062–9.
24. Liguori A, Casini A, Di Loreto M et al. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur J Clin Pharmacol 1999; 55 (2): 117–24.
25. de Berrazueta JR, González JP, de Mier I et al. Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. J Cardiovasc Pharmacol 2007; 49 (2): 90–5.
26. Uchida T, Yamanaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl. 2): 14–7.
27. Goodfriend TL, Ball DL, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): 45–50.
28. Uchida T, Yananaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145–50.
29. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–30.
30. Ishido H, Senzaki H. Torasemide for the treatment of heart failure. Cardiovasc Hematol Disord Drug Targets 2008; 8 (2): 127–32.
31. Yamanaga K, Uchida T, Kido H et al. Torasemide, but not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
32. Агеев Ф.Т., Жубрина Е.С., Гиляревский С.Р. и др. Сравнительная эффективность и безопасность длительного применения торасемида у больных с компенсированной сердечной недостаточностью. Влияние на маркеры фиброза миокарда. Сердечная недостаточность. 2013; 14 (2): 55–62.
[Ageev F.T., Zhubrina E.S., Giliarevskii S.R. et al. Sravnitel'naia effektivnost' i bezopasnost' dlitel'nogo primeneniia torasemida u bol'nykh s kompensirovannoi serdechnoi nedostatochnost'iu. Vliianie na markery fibroza miokarda. Serdechnaia nedostatochnost'. 2013; 14 (2): 55–62 (in Russian).]
33. Watanabe K, Sreedhar R, Thandavarayan RA et al. Comparative effects of torasemide and furosemide on gap junction proteins and cardiac fibrosis in a rat model of dilated cardiomyopathy. Biofactors 2017; 43 (2): 187–94.
34. Broekhuysen J, Deger F, Douchamps J et al. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol 1986; 31 (Suppl.): 29–34.
35. Vargo DL, Kramer WG, Black PK et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57 (6): 601–9.
36. Reyes AJ. Diuretics in the therapy of hypertension. J Hum Hypertens 2002; 16 (Suppl. 1): S78-83.
37. Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 1986; 31 (Suppl.): 35–42.
38. Hermida RC, Ayala DE, Mojón A et al. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int 2008; 25 (6): 950–70.
39. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs of today 1994; 8: 1–28.
40. Brunner G, Von Bergmann K, Hacker W et al. Comparison of diuretic effects and pharmacokinetics of torasemid and furosemid after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzt-Forsch/Drug Res 1998; 38: 176–9.
41. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92.
42. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 (Suppl. 3): S32-9.
43. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
44. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–42.
45. Coca A. Long-term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens 2001; 14: 116A.
46. Карпов Ю.А. Торасемид: рекомендации для клинического применения при хронической сердечной недостаточности и артериальной гипертензии. РМЖ. 2014; 23: 1676–81.
[Karpov Iu.A. Torasemid: rekomendatsii dlia klinicheskogo primeneniia pri khronicheskoi serdechnoi nedostatochnosti i arterial'noi gipertenzii. RMZh. 2014; 23: 1676–81 (in Russian).]
47. DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol 2012; 8 (5): 707–28.
48. Murray M, Deer M, Ferguson J et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111 (7): 513–20.
49. Dodion L, Ambroes Y, Lameire N. A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers. Eur J Clin Pharmacol 1986; 31 (Suppl.): 21–7.
50. Patterson J, Adams K, Applefeld M et al. Oral torasemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torasemide Investigators Group. Pharmacotherapy 1994; 14 (5): 514–21.
51. Spannheimer A, Muller K, Falkenstein P et al. Long-term diuretic treatment in heart failure: are there differences between furosemide end torasemide? Praxis (Bern 1994) 2002; 91 (37): 1467–75.
52. Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoenomic аssessment of torasemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther 1999; 21 (5): 854–6.
53. Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507–13.
54. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulat J 2003; 67 (5): 384–90.
55. Balsam P, Ozierański K, Tymińska A. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure – TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18 (1): 36.
56. Malha L, Mann SJ. Loop Diuretics in the Treatment of Hypertension. Curr Hypertens Rep 2016; 18 (4): 27.
57. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Диyретическая терапия эффективными дозами пероральных диуретиков торасемида и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ-ХСН). Сердечная недостаточность. 2011; 12 (3): 3–10.
[Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Diyreticheskaia terapiia effektivnymi dozami peroral'nykh diuretikov torasemida i furosemida v lechenii bol'nykh s obostreniem Khronicheskoi Serdechnoi Nedostatochnosti (DUEL'-KhSN). Serdechnaia nedostatochnost'. 2011; 12 (3): 3–10 (in Russian).]
58. Беркинбаев С.Ф., Джунусбекова Г.А., Исабекова А.Х. Клиническая эффективность петлевого диуретика торасемида в лечении больных хронической сердечной недостаточностью. Результаты казахстанского многоцентрового исследования «ПОЭТ». Рацион. фармакотерапия в кардиологии. 2014; 10 (5): 495–9.
[Berkinbaev S.F., Dzhunusbekova G.A., Isabekova A.Kh. Klinicheskaia effektivnost' petlevogo diuretika torasemida v lechenii bol'nykh khronicheskoi serdechnoi nedostatochnost'iu. Rezul'taty kazakhstanskogo mnogotsentrovogo issledovaniia "POET'. Ratsion. farmakoterapiia v kardiologii. 2014; 10 (5): 495–9 (in Russian).]
59. Аверин Е.Е. Влияние торасемида на гипертрофию миокарда левого желудочка.  Сердечная недостаточность. 2012; 3 (71): 158–61.
[Averin E.E. Vliianie torasemida na gipertrofiiu miokarda levogo zheludochka.  Serdechnaia nedostatochnost'. 2012; 3 (71): 158–61 (in Russian).]
60. Anguita M, Toledano F, León C, Castillo JC. Hypertension, hypertensive heart disease and heart failure. Role of loop diuretics. Med Clin (Barc) 2008; 131 (17): 660–4.
61. Барышникова Г.А., Аверин Е.Е. Применение диуретиков при артериальной гипертензии: преимущества торасемида. Эффективная фармакотерапия. 2013; 33: 24–32.
[Baryshnikova G.A., Averin E.E. Primenenie diuretikov pri arterial'noi gipertenzii: preimushchestva torasemida. Effektivnaia farmakoterapiia. 2013; 33: 24–32 (in Russian).]
62. Потешкина Н.Г., Трошина А.А. Торасемид в лечении кардиоваскулярной патологии: оптимальное применение в условиях коморбидности. Системные гипертензии. 2015; 4: 38–41.
[Poteshkina N.G., Troshina A.A. Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity. Systemic Hypertension. 2015; 12 (4): 38–41 (in Russian).]
63. Никулина Н.Н., Якушин С.С. Возможности использования современного петлевого диуретика торасемида в комплексной антигипертензивной терапии. Consilium Medicum. 2016; 18 (5): 30–5.
[Nikulina N.N., Iakushin S.S. Vozmozhnosti ispol'zovaniia sovremennogo petlevogo diuretika torasemida v kompleksnoi antigipertenzivnoi terapii. Consilium Medicum. 2016; 18 (5): 30–5 (in Russian).]
64. Гуревич М.А. Петлевой диуретик торасемид – механизмы действия, клиническое использование при неосложненной форме артериальной гипертонии. Трудный пациент. 2018; 7: 17–9.
[Gurevich M.A. Petlevoi diuretik torasemid – mekhanizmy deistviia, klinicheskoe ispol'zovanie pri neoslozhnennoi forme arterial'noi gipertonii. Trudnyi patsient. 2018; 7: 17–9 (in Russian).]
65. Трухан Д.И., Викторова И.А. Диуретики в лечении артериальной гипертонии: выбор препарата с позиции рациональной фармакотерапии и фармакоэкономической эффективности. Справочник поликлинического врача. 2011; 8: 31–4.
[Trukhan D.I., Viktorova I.A. Diuretiki v lechenii arterial'noi gipertonii: vybor preparata s pozitsii ratsional'noi farmakoterapii i farmakoekonomicheskoi effektivnosti. Handbook for Practitioners Doctors. 2011; 8: 31–4 (in Russian).]
66. Павлова Т.В. Роль диуретиков в лечении АГ. Справочник поликлинического врача. 2013; 7: 37–41.
[Pavlova T.V. Rol' diuretikov v lechenii AG. Handbook for Practitioners Doctors. 2013; 7: 37–41 (in Russian).]
67. Трухан Д.И., Поздняков Ю.М. Выбор диуретика для лечения артериальной гипертензии с позиций рациональной фармакотерапии. Справочник поликлинического врача. 2015; 10: 4–9.
[Trukhan D.I., Pozdniakov Iu.M. Vybor diuretika dlia lecheniia arterial'noi gipertenzii s pozitsii ratsional'noi farmakoterapii. Handbook for Practitioners Doctors. 2015; 10: 4–9 (in Russian).]
68. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19 (1): 5–13.
69. Морозова Т.Е., Юдина И.Ю. Диуретики в лечении артериальной гипертензии: место торасемида. Consilum Medicum. 2015; 17 (5): 14–8.
[Morozova T.E., Yudina I.Yu. Diuretics in the treatment of arterial hypertension: the role of torasemide. Consilum Medicum. 2015; 17 (5): 14–8 (in Russian).]
70. Леонова М.В. Место диуретиков в терапии артериальной гипертонии: фокус на новый петлевой диуретик торасемид. Consilium Medicum. 2015; 17 (10): 23–6.
[Leonova M.V. The role of diuretics in the treatment of arterial hypertension: focus on new loop diuretic – torasemide. Consilium Medicum. 2015; 17 (10): 23–6 (in Russian).]
71. Сычев Д.А. Торасемид. Справочник поликлинического врача. 2015; 1: 54–5.
[Sychev D.A. Torasemid. Handbook for Practitioners Doctors. 2015; 1: 54–5 (in Russian).]
72. Леонова М.В., Алимова Э.Э., Еремина Ю.Н. Клиническая фармакология торасемида: особенности фармакокинетики и фармакогенетики. Consilium Medicum. 2016; 18 (12): 44–8.
[Leonova M.V., Alimova E.E., Eremina Yu.N. Torasemide clinical pharmacology: pharmacokinetics and pharmacogenetics. Consilium Medicum. 2016; 18 (12): 44–8. (in Russian).]
73. Барышникова Г.А., Чорбинская С.А. Диуретики в лечении артериальной гипертонии. Что нового? Consilium Medicum. 2017; 19 (1): 13–7.
[Baryshnikova G.A., Chorbinskaia S.A. Diuretics in the treatment of arterial hypertension. What's new? Consilium Medicum. 2017; 19 (1): 13–7 (in Russian).]
74. Морозова Т.Е., Юдина И.Ю. Выбор диуретических лекарственных средств для лечения артериальной гипертензии в амбулаторно-поликлинической практике. Справочник поликлинического врача. 2017; 3: 38–42.
[Morozova T.E., Yudina I.Yu. Selection of diuretic drugs for the treatment of hypertension in outpatient clinic practice. Handbook for Practitioners Doctors. 2017; 3: 38–42 (in Russian).]
75. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
76. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 169–81.
77. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
78. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
79. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 183–209.
80. Friedel H, Buckley MM. Torasemide: а review of its pharmacology and therapeutic potential. Drugs 1991; 41 (1): 81–103.
81. Преображенский Д.В., Сидоренко Б.А., Вышинская И.Д. и др. Торасемид – революционный петлевой диуретик: особенности фармакологии и клиническая эффективность. Сердце: журнал для практикующих врачей. 2007; 6 (2): 69–74.
[Preobrazhenskii D.V., Sidorenko B.A., Vyshinskaia I.D. et al. Torasemid – revoliutsionnyi petlevoi diuretik: osobennosti farmakologii i klinicheskaia effektivnost'. Serdtse: zhurnal dlia praktikuiushchikh vrachei. 2007; 6 (2): 69–74 (in Russian).]
82. Федеральная служба по надзору в сфере здравоохранения. Информационное письмо от 26.12.2018 № 01И-3093/18. О новых данных по безопасности лекарственных препаратов, содержащих в качестве действующего вещества гидрохлоротиазид. URL: http://roszdravnadzor.ru/drugs/monitpringlp/documents/56341
[Federal'naia sluzhba po nadzoru v sfere zdravookhraneniia. Informatsionnoe pis'mo ot 26.12.2018 № 01I-3093/18. O novykh dannykh po bezopasnosti lekarstvennykh preparatov, soderzhashchikh v kachestve deistvuiushchego veshchestva gidrokhlorotiazid. URL: http://roszdravnadzor.ru/drugs/monitpringlp/documents/56341 (in Russian).]
83. Pottegård A, Hallas J, Olesen M et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282 (4): 322–31. DOI: 10.1111/joim.12629
84. Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78 (4): 673–81.e9. DOI: 10.1016/j.jaad.2017.11.042.
85. Федеральная служба по надзору в сфере здравоохранения. Информационное письмо от 05.02.2019 № 01И-318/19. О внесении изменений в инструкции по применению лекарственных препаратов, содержащих гидрохлоротиазид. URL: http://roszdravnadzor.ru/drugs/monitpringlp/documents/57228
[Federal'naia sluzhba po nadzoru v sfere zdravookhraneniia. Informatsionnoe pis'mo ot 05.02.2019 № 01I-318/19. O vnesenii izmenenii v instruktsii po primeneniiu lekarstvennykh preparatov, soderzhashchikh gidrokhlorotiazid. URL: http://roszdravnadzor.ru/drugs/monitpringlp/documents/57228 (in Russian).]
86. Ткачева О.Н., Шарашкина Н.В., Новикова И.М., Чухарева Н.А. Сравнительное исследование эффектов торасемида и гидрохлортиазида в комбинированном лечении гипертонической болезни у женщин в постменопаузе. Сердце: журнал для практикующих врачей. 2011; 10 (3): 156–60.
[Tkacheva O.N., Sharashkina N.V., Novikova I.M., Chukhareva N.A. Sravnitel'noe issledovanie effektov torasemida i gidrokhlortiazida v kombinirovannom lechenii gipertonicheskoi bolezni u zhenshchin v postmenopauze. Serdtse: zhurnal dlia praktikuiushchikh vrachei. 2011; 10 (3): 156–60 (in Russian).]
87. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2.5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 211–20.
88. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
89. Knauf H, Mutschler E, Velazquez H et al. Torasemide significantly reduces thiazide-induced porassium and magnesium loss despite supraadditive natriuresis. Eur J Clin Pharmacol 2009; 65: 465–72.
90. Перепеч Н.Б. Патогенетическая терапия хронической сердечной недостаточности: позиция торасемида. Системные гипертензии. 2015; 12 (3): 56–62.
[Perepech N.B. Pathogenetic therapy of chronic heart failure: the position of torasemide. Systemic Hypertension. 2015; 12 (3): 56–62 (in Russian).]
91. Кириченко А.А. Петлевые диуретики в лечении артериальной гипертензии и отечного синдрома. Системные гипертензии. 2016; 13 (1): 47–51.
[Kirichenko A.A. Loop diuretics in the treatment of hypertension and edema syndrome. Systemic Hypertansion. 2016; 13 (1): 47–51 (in Russian).]
92. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6–31. DOI: 10.26442/2075082X.2019.1.190179
[Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16 (1): 6–31. DOI: 10.26442/2075082X.2019.1.190179 (in Russian).]
93. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 15 (11): 45–9.
[Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9 (in Russian).]
94. Трухан Д.И. Рациональная фармакотерапия в кардиологии сквозь призму коморбидности и лекарственной безопасности. Справочник поликлинического врача. 2015; 1: 26–31.
[Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31 (in Russian).]
95. Барышникова Г.А. Роль петлевых диуретиков в клинической практике. Справочник поликлинического врача. 2010; 10: 6–10.
[Baryshnikova G.A. Rol' petlevykh diuretikov v klinicheskoi praktike. Handbook for Practitioners Doctors. 2010; 10: 6–10 (in Russian).]
96. Мухин Н.А., Фомин В.В., Пулин А.А. Проблема резистентности к диуретикам: причины и возможные пути решения. Справочник поликлинического врача. 2011; 2: 29–32.
[Mukhin N.A., Fomin V.V., Pulin A.A. Problema rezistentnosti k diuretikam: prichiny i vozmozhnye puti resheniia. Handbook for Practitioners Doctors. 2011; 2: 29–32 (in Russian).]
97. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Лечение больных с обострением хронической сердечной недостаточности: фокус на пероральные диуретики. Справочник поликлинического врача. 2011;  3: 32–7.
[Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Lechenie bol'nykh s obostreniem khronicheskoi serdechnoi nedostatochnosti: fokus na peroral'nye diuretiki. Handbook for Practitioners Doctors. 2011; 3: 32–7 (in Russian).]
98. Барышникова Г.А., Степанова И.И. Фуросемид и торасемид: сходство и различия. Справочник поликлинического врача. 2011; 4: 26–9.
[Baryshnikova G.A., Stepanova I.I. Furosemid i torasemid: skhodstvo i razlichiia. Handbook for Practitioners Doctors. 2011; 4: 26–9 (in Russian).]

________________________________________________

1. Demograficheskii ezhegodnik Rossii. 2013. http://www.gks.ru/bgd/regl/ B13_16/Main. htm (in Russian).
2. Trukhan D.I., Viktorova I.A. Internal Medicine: Cardiology. Rheumatology. Moscow: OOO "Meditsinskoe informatsionnoe agentstvo", 2013 (in Russian).
3. Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). Obshchestvo spetsialistov po serdechnoi nedostatochnosti. Rossiiskoe kardiologicheskoe obshchestvo. 2016. URL: http://ossn.ru/upload/medialibrary/003/97_30012017.pdf (in Russian).
4. Fomin I.V. Khronicheskaia serdechnaia nedostatochnost' v Rossiiskoi Federatsii: chto segodnia my znaem i chto dolzhny delat'. Ros. kardiol. zhurn. 2016; 8: 7–13 (in Russian).
5. Mareev V.Iu., Ageev F.T., Arutiunov G.P. et al. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr) Zhurn. Serdechnaia Nedostatochnost'. 2013; 7 (81): 379–472 (in Russian).
6. Trukhan D.I., Filimonov S.N. Bolezni serdechno-sosudistoi sistemy: klinika, diagnostika i lechenie. Saint Petersburg: SpetsLit, 2016 (in Russian).
7. Temnikova E.A., Filimonov S.N., Trukhan D.I. Geriatricheskie aspekty zabolevanii serdechno-sosudistoi sistemy. Novokuznetsk: Poligrafist, 2019 (in Russian).
8. Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. et al. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiolog. zhurn. 2006; 4: 45–50 (in Russian).
9. Shal'nova S., Kukushkin S., Manoshkina E., Timofeeva T. Arterial'naia gipertenziia i priverzhennost' terapii. Vrach. 2009; 12: 39–42 (in Russian).
10. Trukhan D.I. Treatment of chronic heart failure and arterial hypertension: two aims and one drug – torasemide. Consilium Medicum. 2017; 19 (10): 79–84. DOI: 10.26442/2075-1753_19.10.79-84 (in Russian).
11. Trukhan D.I. Treatment of chronic heart failure and arterial hypertension: two aims and one drug – fosinopril. Consilium Medicum. 2018; 20 (5): 50–55. DOI: 10.26442/2075-1753_2018.5.50-55 (in Russian).
12. Masereel B, Ferrari P, Ferrandi M et al. Na+, 2Cl-, K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
13. Diuver (Diuver) instruktsiia po primeneniiu. URL: https://www.vidal.ru/drugs/diuver__8865 (in Russian).
14. Reyes AJ. Effects of diuretics on renal excretory function. Eur Heart J 1992; 13 (Suppl. G): 15–21.
15. Bolke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs of Today 1994; 30 (8): 1–28.
16. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–42.
17. Fortuno A, Muniz P, Ravassa S et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 1999; 34 (1): 138–43.
18. Spieker C, Zidek W, Hacker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1A): 188–90.
19. López B, Querejeta R, González A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43 (11): 2028–35.
20. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
21. Kasama S, Toyama T, Sumino H et al. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. Int J Cardiol 2013; 167 (1): 244–9.
22. Harada K, Izawa H, Nishizawa T et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol 2009; 53 (6): 468–73.
23. Guan Z, Pollock JS, Cook AK et al. Effect of epithelial sodium channel blockade on the myogenic response of rat juxtamedullary afferent arterioles. Hypertension 2009; 54 (5): 1062–9.
24. Liguori A, Casini A, Di Loreto M et al. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur J Clin Pharmacol 1999; 55 (2): 117–24.
25. de Berrazueta JR, González JP, de Mier I et al. Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. J Cardiovasc Pharmacol 2007; 49 (2): 90–5.
26. Uchida T, Yamanaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl. 2): 14–7.
27. Goodfriend TL, Ball DL, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): 45–50.
28. Uchida T, Yananaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145–50.
29. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–30.
30. Ishido H, Senzaki H. Torasemide for the treatment of heart failure. Cardiovasc Hematol Disord Drug Targets 2008; 8 (2): 127–32.
31. Yamanaga K, Uchida T, Kido H et al. Torasemide, but not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
32. Ageev F.T., Zhubrina E.S., Giliarevskii S.R. et al. Sravnitel'naia effektivnost' i bezopasnost' dlitel'nogo primeneniia torasemida u bol'nykh s kompensirovannoi serdechnoi nedostatochnost'iu. Vliianie na markery fibroza miokarda. Serdechnaia nedostatochnost'. 2013; 14 (2): 55–62 (in Russian).
33. Watanabe K, Sreedhar R, Thandavarayan RA et al. Comparative effects of torasemide and furosemide on gap junction proteins and cardiac fibrosis in a rat model of dilated cardiomyopathy. Biofactors 2017; 43 (2): 187–94.
34. Broekhuysen J, Deger F, Douchamps J et al. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol 1986; 31 (Suppl.): 29–34.
35. Vargo DL, Kramer WG, Black PK et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57 (6): 601–9.
36. Reyes AJ. Diuretics in the therapy of hypertension. J Hum Hypertens 2002; 16 (Suppl. 1): S78-83.
37. Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 1986; 31 (Suppl.): 35–42.
38. Hermida RC, Ayala DE, Mojón A et al. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int 2008; 25 (6): 950–70.
39. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs of today 1994; 8: 1–28.
40. Brunner G, Von Bergmann K, Hacker W et al. Comparison of diuretic effects and pharmacokinetics of torasemid and furosemid after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzt-Forsch/Drug Res 1998; 38: 176–9.
41. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92.
42. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 (Suppl. 3): S32-9.
43. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
44. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49 (1): 121–42.
45. Coca A. Long-term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens 2001; 14: 116A.
46. Karpov Iu.A. Torasemid: rekomendatsii dlia klinicheskogo primeneniia pri khronicheskoi serdechnoi nedostatochnosti i arterial'noi gipertenzii. RMZh. 2014; 23: 1676–81 (in Russian).
47. DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol 2012; 8 (5): 707–28.
48. Murray M, Deer M, Ferguson J et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111 (7): 513–20.
49. Dodion L, Ambroes Y, Lameire N. A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers. Eur J Clin Pharmacol 1986; 31 (Suppl.): 21–7.
50. Patterson J, Adams K, Applefeld M et al. Oral torasemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torasemide Investigators Group. Pharmacotherapy 1994; 14 (5): 514–21.
51. Spannheimer A, Muller K, Falkenstein P et al. Long-term diuretic treatment in heart failure: are there differences between furosemide end torasemide? Praxis (Bern 1994) 2002; 91 (37): 1467–75.
52. Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoenomic аssessment of torasemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther 1999; 21 (5): 854–6.
53. Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507–13.
54. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulat J 2003; 67 (5): 384–90.
55. Balsam P, Ozierański K, Tymińska A. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure – TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18 (1): 36.
56. Malha L, Mann SJ. Loop Diuretics in the Treatment of Hypertension. Curr Hypertens Rep 2016; 18 (4): 27.
57. Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Diyreticheskaia terapiia effektivnymi dozami peroral'nykh diuretikov torasemida i furosemida v lechenii bol'nykh s obostreniem Khronicheskoi Serdechnoi Nedostatochnosti (DUEL'-KhSN). Serdechnaia nedostatochnost'. 2011; 12 (3): 3–10 (in Russian).
58. Berkinbaev S.F., Dzhunusbekova G.A., Isabekova A.Kh. Klinicheskaia effektivnost' petlevogo diuretika torasemida v lechenii bol'nykh khronicheskoi serdechnoi nedostatochnost'iu. Rezul'taty kazakhstanskogo mnogotsentrovogo issledovaniia "POET'. Ratsion. farmakoterapiia v kardiologii. 2014; 10 (5): 495–9 (in Russian).
59. Averin E.E. Vliianie torasemida na gipertrofiiu miokarda levogo zheludochka.  Serdechnaia nedostatochnost'. 2012; 3 (71): 158–61 (in Russian).
60. Anguita M, Toledano F, León C, Castillo JC. Hypertension, hypertensive heart disease and heart failure. Role of loop diuretics. Med Clin (Barc) 2008; 131 (17): 660–4.
61. Baryshnikova G.A., Averin E.E. Primenenie diuretikov pri arterial'noi gipertenzii: preimushchestva torasemida. Effektivnaia farmakoterapiia. 2013; 33: 24–32 (in Russian).
62. Poteshkina N.G., Troshina A.A. Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity. Systemic Hypertension. 2015; 12 (4): 38–41 (in Russian).
63. Nikulina N.N., Iakushin S.S. Vozmozhnosti ispol'zovaniia sovremennogo petlevogo diuretika torasemida v kompleksnoi antigipertenzivnoi terapii. Consilium Medicum. 2016; 18 (5): 30–5 (in Russian).
64. Gurevich M.A. Petlevoi diuretik torasemid – mekhanizmy deistviia, klinicheskoe ispol'zovanie pri neoslozhnennoi forme arterial'noi gipertonii. Trudnyi patsient. 2018; 7: 17–9 (in Russian).
65. Trukhan D.I., Viktorova I.A. Diuretiki v lechenii arterial'noi gipertonii: vybor preparata s pozitsii ratsional'noi farmakoterapii i farmakoekonomicheskoi effektivnosti. Handbook for Practitioners Doctors. 2011; 8: 31–4 (in Russian).
66. Pavlova T.V. Rol' diuretikov v lechenii AG. Handbook for Practitioners Doctors. 2013; 7: 37–41 (in Russian).
67. Trukhan D.I., Pozdniakov Iu.M. Vybor diuretika dlia lecheniia arterial'noi gipertenzii s pozitsii ratsional'noi farmakoterapii. Handbook for Practitioners Doctors. 2015; 10: 4–9 (in Russian).
68. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19 (1): 5–13.
69. Morozova T.E., Yudina I.Yu. Diuretics in the treatment of arterial hypertension: the role of torasemide. Consilum Medicum. 2015; 17 (5): 14–8 (in Russian).
70. Leonova M.V. The role of diuretics in the treatment of arterial hypertension: focus on new loop diuretic – torasemide. Consilium Medicum. 2015; 17 (10): 23–6 (in Russian).
71. Sychev D.A. Torasemid. Handbook for Practitioners Doctors. 2015; 1: 54–5 (in Russian).
72. Leonova M.V., Alimova E.E., Eremina Yu.N. Torasemide clinical pharmacology: pharmacokinetics and pharmacogenetics. Consilium Medicum. 2016; 18 (12): 44–8. (in Russian).
73. Baryshnikova G.A., Chorbinskaia S.A. Diuretics in the treatment of arterial hypertension. What's new? Consilium Medicum. 2017; 19 (1): 13–7 (in Russian).
74. Morozova T.E., Yudina I.Yu. Selection of diuretic drugs for the treatment of hypertension in outpatient clinic practice. Handbook for Practitioners Doctors. 2017; 3: 38–42 (in Russian).
75. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
76. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 169–81.
77. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
78. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
79. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 183–209.
80. Friedel H, Buckley MM. Torasemide: а review of its pharmacology and therapeutic potential. Drugs 1991; 41 (1): 81–103.
81. Preobrazhenskii D.V., Sidorenko B.A., Vyshinskaia I.D. et al. Torasemid – revoliutsionnyi petlevoi diuretik: osobennosti farmakologii i klinicheskaia effektivnost'. Serdtse: zhurnal dlia praktikuiushchikh vrachei. 2007; 6 (2): 69–74 (in Russian).
82. Federal'naia sluzhba po nadzoru v sfere zdravookhraneniia. Informatsionnoe pis'mo ot 26.12.2018 № 01I-3093/18. O novykh dannykh po bezopasnosti lekarstvennykh preparatov, soderzhashchikh v kachestve deistvuiushchego veshchestva gidrokhlorotiazid. URL: http://roszdravnadzor.ru/drugs/monitpringlp/documents/56341 (in Russian).
83. Pottegård A, Hallas J, Olesen M et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282 (4): 322–31. DOI: 10.1111/joim.12629
84. Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78 (4): 673–81.e9. DOI: 10.1016/j.jaad.2017.11.042.
85. Federal'naia sluzhba po nadzoru v sfere zdravookhraneniia. Informatsionnoe pis'mo ot 05.02.2019 № 01I-318/19. O vnesenii izmenenii v instruktsii po primeneniiu lekarstvennykh preparatov, soderzhashchikh gidrokhlorotiazid. URL: http://roszdravnadzor.ru/drugs/monitpringlp/documents/57228 (in Russian).
86. Tkacheva O.N., Sharashkina N.V., Novikova I.M., Chukhareva N.A. Sravnitel'noe issledovanie effektov torasemida i gidrokhlortiazida v kombinirovannom lechenii gipertonicheskoi bolezni u zhenshchin v postmenopauze. Serdtse: zhurnal dlia praktikuiushchikh vrachei. 2011; 10 (3): 156–60 (in Russian).
87. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2.5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 211–20.
88. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
89. Knauf H, Mutschler E, Velazquez H et al. Torasemide significantly reduces thiazide-induced porassium and magnesium loss despite supraadditive natriuresis. Eur J Clin Pharmacol 2009; 65: 465–72.
90. Perepech N.B. Pathogenetic therapy of chronic heart failure: the position of torasemide. Systemic Hypertension. 2015; 12 (3): 56–62 (in Russian).
91. Kirichenko A.A. Loop diuretics in the treatment of hypertension and edema syndrome. Systemic Hypertansion. 2016; 13 (1): 47–51 (in Russian).
92. Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16 (1): 6–31. DOI: 10.26442/2075082X.2019.1.190179 (in Russian).
93. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9 (in Russian).
94. Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31 (in Russian).
95. Baryshnikova G.A. Rol' petlevykh diuretikov v klinicheskoi praktike. Handbook for Practitioners Doctors. 2010; 10: 6–10 (in Russian).
96. Mukhin N.A., Fomin V.V., Pulin A.A. Problema rezistentnosti k diuretikam: prichiny i vozmozhnye puti resheniia. Handbook for Practitioners Doctors. 2011; 2: 29–32 (in Russian).
97. Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Lechenie bol'nykh s obostreniem khronicheskoi serdechnoi nedostatochnosti: fokus na peroral'nye diuretiki. Handbook for Practitioners Doctors. 2011; 3: 32–7 (in Russian).
98. Baryshnikova G.A., Stepanova I.I. Furosemid i torasemid: skhodstvo i razlichiia. Handbook for Practitioners Doctors. 2011; 4: 26–9 (in Russian).

Д.И. Трухан*1, Е.Л. Давыдов2

1 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия;
2 ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого», Красноярск, Россия
*dmitry_trukhan@mail.ru

________________________________________________

Dmitry I. Trukhan*1, Evgeny L. Davydov2

1 Omsk State Medical University, Omsk, Russia;
2 Voino-Yasenetski Krasnoyarsk State Medical University, Krasnoyarsk, Russia
*dmitry_trukhan@mail.ru